The use of animal models for cancer chemoprevention drug development.

Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, MD, USA.
Seminars in Oncology (Impact Factor: 3.94). 08/2010; 37(4):327-38. DOI: 10.1053/j.seminoncol.2010.05.010
Source: PubMed

ABSTRACT Animal models currently are used to assess the efficacy of potential chemopreventive agents, including synthetic chemicals, chemical agents obtained from natural products, and natural product mixtures. The observations made in these models as well as other data are then used to prioritize agents to determine which are qualified to progress to clinical chemoprevention trials. Organ-specific animal models are employed to determine which agents or classes of agents are likely to be the most effective at nontoxic doses to prevent organ-specific forms of cancer. These results are then used to target specific organs in high-risk populations in clinical trials. The animal models used are either carcinogen-induced with carcinogens specific for particular organ sites or they are transgenic/mutant animals with insertions, deletions, or mutations at targeted gene sites known to enhance cancers in a specific organ. Animal tumor models with characteristics favorable to chemoprevention studies are available for cancers of the lung, colon, skin, bladder, mammary, prostate, head and neck, esophagus, ovary, and pancreas. In addition to single-agent dose-response testing, such models are frequently used for testing combinations of agents, testing different routes of administration, evaluating surrogate endpoint biomarkers, and generating initial pharmacokinetics and toxicology data. For some of the more standard animal models there is significant correlation with human chemopreventive trial results. There are a growing number of positive human chemoprevention trials that have used agents or combinations that were positive in animal testing. There have been fewer negative human clinical trials, but their results again correlate with negative animal results. Clearly the validation of animal models to predict the efficacy of agents in human clinical trials will await further human data on positive and negative outcomes with chemopreventive agents. Whether validated or not, animal efficacy data remain central to the clinical trial decision-making process.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Prevention of cancer remains the most promising strategy for reducing both its incidence and the mortality due to this disease. For more than four decades, findings from epidemiology, basic research and clinical trials have informed the development of lifestyle and medical approaches to cancer prevention. These include selective oestrogen receptor modulators and aromatase inhibitors for breast cancer, the 5-α-reductase inhibitors finasteride and dutasteride for prostate cancer, and the development of vaccines for viruses that are associated with specific cancers. Future directions include genetic, proteomic and other molecular approaches for identifying pathways that are associated with cancer initiation and development, as well as refining the search for immunologically modifiable causes of cancer.
    Nature Reviews Cancer 11/2012; DOI:10.1038/nrc3397 · 29.54 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Urinary bladder cancer is a major human malignancy that afflicts millions of people worldwide every year. Urinary bladder cancer is usually superficial at presentation in 70 - 80% of patients. In these cases, a simple transurethral resection is adequate for removing the tumor. However, some patients experience recurrence or even tumor progression. In another 20 - 30% of patients, muscle-invasive carcinoma is diagnosed. Despite all the developments in this area, even today, the options for treatment of urinary bladder cancer remain inadequate. The search for the mechanisms involved in human urinary bladder cancer and for new and improved treatment methods has led to the development of many experimental models using laboratory animals over the past 40 years. Areas covered: In this review, the authors provide a concise overview of the animal models used to study urinary bladder cancer. Furthermore, the authors discuss their advantages and disadvantages with regard to the search for new therapeutic approaches. Expert opinion: The use of urinary bladder cancer models for understanding the mechanisms involved in tumors' response to new treatments is an important step in the drug discovery process. However, the authors believe that it will be necessary to develop our knowledge and understanding of the molecular processes underlying urothelial chemical carcinogenesis for us to better evaluate the efficacy of novel therapeutics.
    Expert Opinion on Drug Discovery 03/2014; DOI:10.1517/17460441.2014.902930 · 3.47 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Açai, fruit from Euterpe oleraceae Martius, is consumed in natura and in a variety of beverages and food preparations and possesses several potential antioxidant compounds. In a first study for anticarcinogenicity screening, male Swiss mice (n = 20/per group) were chemically-induced to urothelial bladder carcinogenesis for 10 weeks and received a standard diet or a standard diet containing 2.5 and 5 % spray-dried açai pulp (AP) for 10 weeks. At week 20, the incidence of simple and nodular hyperplasia and the incidence and multiplicity of transitional cell carcinoma (TCC) were evaluated. In a second study for antigenotoxicity screening, male Swiss mice (n = 6/per group) were fed standard diet or standard diet containing 5 % AP for three weeks. Urothelial cell suspensions were obtained and challenged with H(2)O(2) for induction of DNA damage and analyzed by comet assay. Overall, dietary 5 % AP reduced TCC incidence and multiplicity (p = 0.019 and p = 0.015, respectively) and tumor cell proliferation and p63 expression (p = 0.02 and p = 0.007, respectively), Furthermore, the group fed the 5 % AP presented a significant reduction (p < 0.01) in DNA damage induced by H(2)O(2), a notable oxidant agent. The results suggest that the spray-dried açai pulp used here inhibits the TCC development in male Swiss mice, probably due to its potential antioxidant action.
    Plant Foods for Human Nutrition 09/2012; 67(3):235-41. DOI:10.1007/s11130-012-0308-y · 2.36 Impact Factor

Full-text (2 Sources)

Available from
Sep 8, 2014